Stock Track | Viking Therapeutics Soars 5.07% as Phase 2b Study Data Boosts Prospects

Stock Track11-20 01:42

Viking Therapeutics (VKTX) saw its shares surge 5.07% on Tuesday, following the announcement of positive results from the company's Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist.

The biotechnology company revealed that it will present the detailed findings from the VOYAGE study in a late-breaker presentation at an upcoming medical conference. Investors are eagerly anticipating the data, as VK2809 is a promising drug candidate targeting non-alcoholic steatohepatitis (NASH), a severe liver disease with no approved treatments currently available.

The positive Phase 2b results have raised hopes for Viking Therapeutics' prospects in the lucrative NASH market, driving significant investor interest and fueling the stock's rally. Analysts will closely examine the data to assess the drug's efficacy, safety, and potential for regulatory approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174320183?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 01:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174320183","market":"us","top_or_hot":-1,"title":"Stock Track | Viking Therapeutics Soars 5.07% as Phase 2b Study Data Boosts Prospects","media":"Stock Track","content":"<p>Viking Therapeutics (VKTX) saw its shares surge 5.07% on Tuesday, following the announcement of positive results from the company's Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist.</p>\n\n<p>The biotechnology company revealed that it will present the detailed findings from the VOYAGE study in a late-breaker presentation at an upcoming medical conference. Investors are eagerly anticipating the data, as VK2809 is a promising drug candidate targeting non-alcoholic steatohepatitis (NASH), a severe liver disease with no approved treatments currently available.</p>\n\n<p>The positive Phase 2b results have raised hopes for Viking Therapeutics' prospects in the lucrative NASH market, driving significant investor interest and fueling the stock's rally. Analysts will closely examine the data to assess the drug's efficacy, safety, and potential for regulatory approval.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viking Therapeutics Soars 5.07% as Phase 2b Study Data Boosts Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viking Therapeutics Soars 5.07% as Phase 2b Study Data Boosts Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-20 01:42 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viking Therapeutics (VKTX) saw its shares surge 5.07% on Tuesday, following the announcement of positive results from the company's Phase 2b clinical trial of VK2809, a novel liver-selective thyroid ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1174320183","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174320183","pubTimestamp":1732038140,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Viking Therapeutics  saw its shares surge 5.07% on Tuesday, following the announcement of positive results from the company's Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist.The biotechnology company revealed that it will present the detailed findings from the VOYAGE study in a late-breaker presentation at an upcoming medical conference. Investors are eagerly anticipating the data, as VK2809 is a promising drug candidate targeting non-alcoholic st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc."},"translate_title":"2b期研究数据提振前景，Viking Therapeutics股价飙升5.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1},"content_text":"Viking Therapeutics (VKTX) saw its shares surge 5.07% on Tuesday, following the announcement of positive results from the company's Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist.\nThe biotechnology company revealed that it will present the detailed findings from the VOYAGE study in a late-breaker presentation at an upcoming medical conference. Investors are eagerly anticipating the data, as VK2809 is a promising drug candidate targeting non-alcoholic steatohepatitis (NASH), a severe liver disease with no approved treatments currently available.\nThe positive Phase 2b results have raised hopes for Viking Therapeutics' prospects in the lucrative NASH market, driving significant investor interest and fueling the stock's rally. Analysts will closely examine the data to assess the drug's efficacy, safety, and potential for regulatory approval.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174320183"}